Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,901 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Local Therapies Clear all
Not yet recruiting Not applicable Interventional

Suicide Safety Planning

NCT07783490
View directory record Official record
Conditions
Suicide Prevention, Suicide Safety Planning, Suicidal Ideation, Suicide Attempt
Interventions
Local Care Continuity, Centralized Care Navigation
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
176,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 3 Interventional

Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy

NCT06215820
View directory record Official record
Conditions
Acute Pain, Post Operative Pain, Pain
Interventions
MR-107A-02, Tramadol, Placebo, Bunionectomy
Drug · Procedure
Lead sponsor
Viatris Specialty LLC
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
15
States / cities
Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device

NCT01618968
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
MTX
Drug
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 2Phase 3 Interventional

Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

NCT00406068
View directory record Official record
Conditions
Bladder Neoplasms
Interventions
Mycobacterial cell wall-DNA complex
Drug
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Phoenix, Arizona • San Diego, California • New Britain, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Sep 2, 2026, 5:47 PM EDT
Active, not recruiting Phase 4 Interventional

Improving Postamputation Functioning by Decreasing Phantom Pain With Perioperative Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study

NCT03461120
View directory record Official record
Conditions
Lower Extremity Surgical Amputation, Post-amputation Phantom Limb Pain
Interventions
Experimental continuous peripheral nerve blocks, Control continuous peripheral nerve blocks
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
8
States / cities
San Diego, California • Boston, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 2, 2026, 5:47 PM EDT
Recruiting Phase 3 Interventional

Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children

NCT06070350
View directory record Official record
Conditions
Hemorrhagic Shock, Trauma Injury
Interventions
Low Titer Group O Whole Blood (LTOWB), Placebo, Tranexamic Acid (TXA), Component Therapy (CT)
Biological · Drug
Lead sponsor
Philip Spinella
Other
Eligibility
Up to 17 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Tucson, Arizona • Little Rock, Arkansas • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 2, 2026, 5:47 PM EDT
Active, not recruiting Not applicable Interventional

HP Arize 3D Orthotics for Planar Fasciitis

NCT05707013
View directory record Official record
Conditions
Plantar Fascitis
Interventions
HP Arize 3D-Printed Orthotics, Traditional Orthotics
Device
Lead sponsor
Prisma Health-Midlands
Other
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Lexington, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 1 Interventional Results available

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

NCT01922076
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Glioblastoma, Gliosarcoma
Interventions
Adavosertib, Laboratory Biomarker Analysis, Pharmacological Study, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
37 Months to 21 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

NCT04401293
View directory record Official record
Conditions
Sars-CoV2, COVID
Interventions
Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Not applicable Interventional

TheraSphere & Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer

NCT04090645
View directory record Official record
Conditions
Liver, Cancer of, Non-Resectable
Interventions
TheraSphere
Device
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 2, 2026, 5:47 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 2, 2026, 5:47 PM EDT
Recruiting No phase listed Observational

Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®

NCT06498128
View directory record Official record
Conditions
Insomnia
Interventions
Daridorexant, Non-orexin receptor antagonist medications for insomnia, No insomnia medication
Drug · Other
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
785 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 2, 2026, 5:47 PM EDT
Completed No phase listed Observational Results available

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT02141438
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
49
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Daly City, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 2, 2026, 5:47 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

RCT for Women With a Persisting Pregnancy of Unknown Location

NCT01800162
View directory record Official record
Conditions
Persistent Pregnancy of Unknown Location, Ectopic Pregnancy
Interventions
Methotrexate, Uterine Evacuation, Expectant Management
Drug · Procedure · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Sep 2, 2026, 5:47 PM EDT
Active, not recruiting Not applicable Interventional

Infusion System for Hepatic Cancer

NCT04684862
View directory record Official record
Conditions
Colorectal Cancer Metastatic to Liver, Intrahepatic Cholangiocarcinoma
Interventions
Medtronic SynchroMed II programmable pump connected to an Intera tapered catheter (Combined Infusion System)
Device
Lead sponsor
Ronald DeMatteo, M.D.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 2, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin

NCT01059305
View directory record Official record
Conditions
Skin Cancer
Interventions
Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 2, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional Results available

Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy

NCT00490490
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Bexxar (tositumomab), External beam radiotherapy (XRT), Potassium Iodide (KI)
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)

NCT00343083
View directory record Official record
Conditions
Cancer of Head and Neck
Interventions
Erbitux, Paclitaxel & Carboplatin, Radiation
Drug · Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Sep 2, 2026, 5:47 PM EDT
Recruiting Phase 2 Interventional

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

NCT05312671
View directory record Official record
Conditions
Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder
Interventions
Atezolizumab, Carboplatin, Cisplatin, Etoposide, Cystectomy
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 2, 2026, 5:47 PM EDT
Recruiting Not applicable Interventional

The Prism Conformity Trial for Post-Traumatic Stress Disorder in Adolescents

NCT06854328
View directory record Official record
Conditions
Post-Traumatic Stress Disorder in Adolescence
Interventions
Prism
Device
Lead sponsor
GrayMatters Health Ltd.
Industry
Eligibility
12 Years to 21 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 2, 2026, 5:47 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

A Clinical Trial Testing Root Coverage With Acellular Dermal Matrix in Thin and Thick Gingival Biotypes

NCT03057730
View directory record Official record
Conditions
Gingival Recession
Interventions
Acellular Dermal Matrix
Biological
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 2, 2026, 5:47 PM EDT
Recruiting Not applicable Interventional

Non-Contact Low-Frequency Ultrasound Vs Standard LaLonde Protocol for Fingertip Injury Wound Healing

NCT06813430
View directory record Official record
Conditions
Non-contact Low Frequency Ultrasound, Lalonde Protocol, Fingertip Amputation
Interventions
Non-contact Low Frequency Ultrasound, Lalonde Protocol (standard of care)
Device · Other
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 2, 2026, 5:47 PM EDT
Recruiting Phase 2 Interventional

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

NCT06463665
View directory record Official record
Conditions
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
Interventions
Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
15
States / cities
Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 2, 2026, 5:47 PM EDT